Core Insights - Orion Group has published its Financial Statement documents for 2025, which include the Financial Statements, Report by the Board of Directors, Sustainability Statement, and Corporate Governance Statement [1][4] - The Financial Statements comply with the European Single Electronic Format (ESEF) reporting requirements and have been audited by KPMG Oy Ab [2] - The Sustainability Statement adheres to the European Sustainability Reporting Standards (ESRS) and has also been assured by KPMG Oy Ab [3] Financial Performance - In 2025, Orion's net sales reached EUR 1,890 million, reflecting the company's strong market position and operational capabilities [6] Corporate Governance - The Remuneration Report for 2025 has been adopted by the Board of Directors and is available in both Finnish and English [5]

Core Viewpoint - Orion Corporation has established a new Long-term Incentive Program for key personnel, aiming to align the interests of shareholders and key individuals to enhance company value and provide competitive rewards based on share performance [1][2]. Group 1: Long-term Incentive Program Details - The Long-term Incentive Program includes performance share plans launched annually, with a three-year earning period for participants to earn class B shares [1]. - The new plan period for the program is set for the calendar years 2026-2028, with the first plan launched in 2025 covering 2025-2027 [2]. - The maximum reward for the 2026-2028 period is capped at 420,000 class B shares, with a total estimated cost of MEUR 26.5 based on share price averages prior to the plan's launch [4]. Group 2: Performance Criteria and Reward Structure - Rewards will be determined based on the achievement of targets related to operating profit, net sales, pipeline and portfolio development, and ESG performance [3]. - The total reward is limited to three times the participant's annual base salary, with a portion paid in cash to cover tax liabilities [5]. Group 3: Company Overview - Orion Corporation is a Nordic pharmaceutical company with over a century of experience, focusing on human and veterinary pharmaceuticals, including proprietary and generic medicines [7]. - In 2025, Orion's net sales reached EUR 1,890 million, and the company employs approximately 4,000 professionals globally [7].

Group 1 - Orion Corporation has converted 62,752 A shares into B shares, which has been officially recorded in the Trade Register on February 3, 2026 [1] - After the conversion, the total number of shares in Orion Corporation is 141,134,278, consisting of 31,524,740 A shares and 109,609,538 B shares [1] - The total number of votes associated with the company's shares after the conversion is 740,104,338 [1] Group 2 - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on developing, manufacturing, and marketing human and veterinary pharmaceuticals [2] - The company reported net sales of EUR 1,542 million in 2024 and employs approximately 3,700 professionals globally [2] - Orion's core therapy areas in pharmaceutical R&D include oncology and pain, with proprietary products aimed at treating cancer, neurological diseases, and respiratory diseases [2]

Group 1 - Orion Corporation has converted 182,827 A shares into B shares, with the conversion recorded on January 16, 2026 [1] - After the conversion, the total number of shares in Orion Corporation is 141,134,278, consisting of 31,587,492 A shares and 109,546,786 B shares [1] - The total number of votes for the company's shares after the conversion is 741,296,626 [1] Group 2 - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience in developing, manufacturing, and marketing human and veterinary pharmaceuticals [2] - The company reported net sales of EUR 1,542 million in 2024 and employs approximately 3,700 professionals globally [2] - Orion's core therapy areas in pharmaceutical R&D include oncology and pain, with proprietary products aimed at treating cancer, neurological diseases, and respiratory diseases [2]

Group 1 - Orion Corporation has converted 182,827 A shares into B shares, with the conversion recorded on January 16, 2026 [1] - After the conversion, the total number of shares in Orion Corporation is 141,134,278, consisting of 31,587,492 A shares and 109,546,786 B shares [1] - The total number of votes for the company's shares after the conversion is 741,296,626 [1] Group 2 - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on human and veterinary pharmaceuticals and active pharmaceutical ingredients [2] - The company reported net sales of EUR 1,542 million in 2024 and employs approximately 3,700 professionals globally [2] - Orion's core therapy areas in pharmaceutical R&D include oncology and pain, with proprietary products aimed at treating cancer, neurological diseases, and respiratory diseases [2]

Core Viewpoint - The Orion Nomination Committee has made recommendations regarding the composition and remuneration of the Board of Directors for the 2026 Annual General Meeting, proposing a total of eight members with specific re-elections and new appointments [1][2]. Board Composition - The proposed Board of Directors will consist of eight members, with six current members re-elected: Kari Jussi Aho, Ari Lehtoranta, Veli-Matti Mattila, Hilpi Rautelin, Henrik Stenqvist, and Karen Lykke Sørensen. New members Minna Maasilta and Sophie Papa are recommended for election [2]. - Veli-Matti Mattila is recommended to continue as Chairman of the Board [2]. - Eija Ronkainen and Maziar Mike Doustdar will not be available for re-election [3]. New Board Members' Background - Minna Maasilta, born in 1986, has a Master of Science (Eng.) and an MBA, with a career in water and environmental engineering, currently serving as Managing Director of Maa- ja vesitekniikan tuki ry [3]. - Sophie Papa, born in 1976, holds multiple degrees including a Bachelor of Arts and a PhD, with extensive experience in medicine and biotechnology, currently a Consulting Venture Partner at RA Capital and Chief Medical Officer at several biotechnology firms [4]. Remuneration Recommendations - The Nomination Committee recommends annual fees: EUR 120,000 for the Chairman, EUR 73,000 for the Vice Chairman, and EUR 60,000 for other members. Additional fees for committee chairpersons are set at EUR 73,000 [6]. - Meeting attendance fees are proposed as EUR 1,200 for the Chairman, EUR 900 for the Vice Chairman, and EUR 600 for other members, with travel expenses covered as per existing practices [7]. - 60% of the annual fees will be paid in cash and 40% in Orion Corporation B shares, with specific amounts allocated for each role [8]. Shareholding Requirements - Board members are required to retain ownership of the Orion Corporation B shares received as fees for two years from the payment date, with conditions for early termination of membership [11]. Additional Information - The Nomination Committee did not provide a recommendation on the remuneration of the Board of Directors, which will be proposed by a shareholder at the Annual General Meeting [12]. - The Nomination Committee consists of members including Hilpi Rautelin as Chair [13].

Core Insights - Orion Pharma has initiated a Phase 2 trial for ODM-212, an oral pan-TEAD inhibitor, targeting malignant pleural mesothelioma (MPM) and epithelioid hemangioendothelioma (EHE), both of which are rare and challenging cancers to treat [1][2][3] Trial Details - The TEADES trial is a multi-center, open-label study enrolling approximately 300 patients with MPM, EHE, or other solid tumors with Hippo pathway dysfunction, focusing on those who have progressed after standard treatments [2] - Primary endpoints include safety and tolerability, while secondary endpoints encompass Overall Response Rate, Progression Free Survival, and Overall Survival [2] Drug Mechanism and Development - ODM-212 functions as a pan-TEAD inhibitor, targeting the Hippo signaling pathway to prevent uncontrolled tumor growth and resistance to therapies by blocking TEAD transcription factors [4] - The first patient was treated in December 2025, marking a significant milestone in the clinical development of ODM-212 [1][3] Cancer Background - Malignant Pleural Mesothelioma (MPM) accounts for 80-90% of mesothelioma cases and is primarily linked to asbestos exposure, with current treatments being limited to chemotherapy and immunotherapy [5] - Epithelioid Hemangioendothelioma (EHE) is an ultra-rare vascular tumor with no standard treatment available, affecting less than one per million people [6] Company Overview - Orion Corporation is a Nordic pharmaceutical company with over a century of experience, focusing on developing, manufacturing, and marketing pharmaceuticals and active ingredients, particularly in oncology and pain management [8]

Group 1 - Orion Corporation has converted 71,498 A shares into B shares, with the conversion recorded in the Trade Register on November 27, 2025 [1] - After the conversion, the total number of shares in Orion Corporation is 141,134,278, consisting of 31,770,319 A shares and 109,363,959 B shares [1] - The total number of votes for the company's shares after the conversion is 744,770,339 [1] Group 2 - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on developing, manufacturing, and marketing human and veterinary pharmaceuticals [2] - The company reported net sales of EUR 1,542 million in 2024 and employs approximately 3,700 professionals globally [2] - Orion's core therapy areas in pharmaceutical R&D include oncology and pain, with proprietary products aimed at treating cancer, neurological diseases, and respiratory diseases [2]

Company Overview - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience in developing, manufacturing, and marketing human and veterinary pharmaceuticals as well as active pharmaceutical ingredients [2] - The company has a diverse portfolio that includes proprietary and generic medicines, as well as consumer health products, focusing on oncology and pain as core therapy areas in its pharmaceutical R&D [2] - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] Share Conversion - A total of 49,164 A shares of Orion Corporation have been converted into B shares, with the conversion recorded in the Trade Register on 24 October 2025 [1] - Following the conversion, the total number of shares in Orion Corporation is 141,134,278, consisting of 31,841,817 A shares and 109,292,461 B shares [1] - The total number of votes associated with the company's shares after the conversion is 746,128,801 [1]

Core Viewpoint - Orion Corporation is set to publish its Interim Report for January–September 2025 on 28 October 2025, with a webcast scheduled for the same day to discuss the report [1][2]. Group 1: Financial Reporting - The Interim Report will be released at approximately 12.00 noon EET on 28 October 2025 [1]. - A live webcast and conference call for analysts, investors, and media representatives will take place at 13.30 EET on the same day [2]. Group 2: Webcast Details - The live webcast link will be available on Orion's website, and a recording will be accessible later the same day [2]. - Participants can join the conference call by registering through a provided link, with access details shared post-registration [3]. Group 3: Company Background - Orion is a Nordic pharmaceutical company with over a hundred years of experience, focusing on developing, manufacturing, and marketing human and veterinary pharmaceuticals [5]. - The company reported net sales of EUR 1,542 million in 2024 and employs approximately 3,700 professionals globally [5].